A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

Eflapegrastim (Rolontis(®)) is a novel, long‐acting hematopoietic growth factor consisting of a recombinant human granulocyte‐colony stimulating factor (rhG‐CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. We report results from a second pivotal, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cobb, Patrick Wayne, Moon, Yong Wha, Mezei, Klára, Láng, István, Bhat, Gajanan, Chawla, Shanta, Hasal, Steven J., Schwartzberg, Lee S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476820/
https://www.ncbi.nlm.nih.gov/pubmed/32687266
http://dx.doi.org/10.1002/cam4.3227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476820/
https://www.ncbi.nlm.nih.gov/pubmed/32687266
http://dx.doi.org/10.1002/cam4.3227

Ejemplares similares